loader2
Partner With Us NRI

Wockhardt Ltd share Price Today

Company details

568.00
598.00
213.00
630.00
6M Return 41.19%
1Y Return 212.45%
Mkt Cap.(Cr) 8,756.90
Volume 281,199
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 281,199

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Wockhardt announced Q4FY24 & FY24 results:

  • YoY growth of 7% in revenue in FY24, Revenue for FY24 of Rs 2,879 crore compared to Rs 2,693 crore in the previous year. QoQ growth of 6%, Revenue for the quarter being Rs 750 crore compared to Rs 710 crore in Q4FY23.
  • YoY growth of 74% in EBITDA in FY24, EBITDA for FY24 at Rs 251 crore compared to Rs 144 crore in the previous year. Quarterly growth in EBITDA by 49% compared to the previous year, EBITDA for Q4FY24 at Rs 70 crore compared to Rs 47 crore in Q4FY23.
  • UK Business stood at Rs 268 crore in Q4FY24 compared to Rs 242 crore in Q4FY23 registering a growth of 11% and contributed about 36% of Global Revenue in the current quarter. UK Business stood at Rs 1,041 crore in FY24 compared to Rs 887 crore in FY23 registering a growth of 17% and contributed about 36% of Global Revenue in FY24.
  • Emerging Markets Business of the Company stood at Rs 190 crore in Q4FY24 contributing to about 25% of the Global Revenue. Emerging Markets Business stood at Rs 642 crore in FY24 compared to Rs 555 crore in FY23 registering a growth of 16% and contributing to about 22% of the Global Revenue.
  • Irish Business stood at Rs 45 crore in Q4FY24 compared to Rs 44 crore in Q4FY23 registering a growth of 4%. Irish Business stood at Rs 179 crore in FY24 compared to Rs 158 crore in FY23 registering a growth of 13%.
  • India Business stood at Rs 181 crore in Q4FY24 compared to Rs 125 crore in the previous year registering a growth of 45%. India business stood at Rs 641 crore compared to Rs 609 crore in FY23 registering a growth of 5% and contributing to 22% of the Global Revenue in FY24.
  • US Business stood at Rs 42 crore in Q4FY24 contributing 6% of the Global Revenue. US Business stood at Rs 175 crore in FY24 contributing 6% of the Global Revenue.

Result PDF

View Other Company Results

Wockhardt Ltd shares SWOT Analysis

Strengths (5)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Rising Net Cash Flow and Cash from Operating activity
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Weakness (8)

  • Red Flag: High Interest Payments Compared to Earnings
  • Promoter holding decreased by more than -2% QoQ
  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years

Opportunity (2)

  • Highest Recovery from 52 Week Low
  • Stock with Low PE (PE < = 10)

Threats (2)

  • Promoter decreasing their shareholding
  • Increasing Trend in Non-Core Income

Resistance and support

R1 589.9
R2 609.0
R3 619.9
Pivot

578.95

S1 559.9
S2 549.0
S3 529.9
EMA SMA
559.0
551.7
521.7
452.6
553.7
558.2
539.3
425.0
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-01-01 456.76 844583 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2024-01-01 456.72 844583 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2023-12-12 397.13 979549 NSE
Name Category Shares
Themisto Trustee Company Private Limited PROMOTER 42.61%
Pasithee Trustee Company Private Limited PROMOTER 3.3%
Ananke Trustee Company Private Limited PROMOTER 2.57%
Callirhoe Trustee Company Private Limited PROMOTER 1.73%
Callirhoe Trustee Company Private Limite PROMOTER 0.61%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Wockhardt Ltd Stocks COMPARISON

Financials( in Cr) Wockhardt Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 570.85 1,516.00 1,564.75 4,588.60 1,109.55
% Change -1.10 0.34 1.31 -0.11 1.75
Mcap Cr 8,756.90 363,739.19 126,332.75 121,813.11 111,646.69
Revenue TTM Cr 2,798.00 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr -472.00 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 0.00 36.34 29.68 76.10 28.94
1 Year Return 212.45 53.43 59.42 31.57 114.34
ROCE -0.86 16.79 14.76 19.30 16.25
ROE -12.34 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 3,359.00 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 32,317.57 -2,589.17
LAST 3M 111,725.82 -36,230.77
LAST 6M 182,653.52 -16,910.03
LAST 12M 290,144.87 98,834.05

Wockhardt Ltd Information

Stock PE (TTM)
0
Promoter Holding
51.6%
Book Value
218.9492
ROCE
-0.86%
ROE
-12.34%
Description
  • Wockhardt Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 5,314.72 crores, it is incorporated in the 1960s. It has reported consolidated sales of Rs. 764.02 crores in December’2020. The company is also listed in the Bombay Stock Exchange (BSE) with the code 532300 and listed in the National Stock Exchange (NSE) with the code WOCKPHARMA.

    Wockhardt is a global biotechnology and pharmaceuticals company with its headquarters based in Mumbai. Wockhardt is engaged in producing biopharmaceuticals, nutrition products, vaccines, formulations, and active pharmaceuticals ingredients (APIs). The company has various manufacturing plants in India and the USA. Notably, more than half of its revenue is generated in Europe. It has a market presence in many countries around the globe, such as India, the USA, UK, Brazil, Russia, Mexico, Kenya, Ghana, etc. Wockhardt Hospitals, a subsidiary of Wockhardt ltd is a healthcare network of tertiary care and super specialty healthcare services in India. These hospitals offer services in the fields of Cardiology, Orthopedics, Neurology, Gastroenterology, Urology, etc. The promoters of the company own 69.68% of the stake in the company, Foreign Institutional Investors (FII) own 2.73%, Domestic Institutional Investors (DII) own 0.09% of the stake, and others (such as public &amp; retail investors) hold the balance of 27.50%.

    In June 2021, quarterly net revenue was Rs. 278.95 crores, which has increased by approximately 57.08 % from Rs. 177.58 crores for the April-June 2020 quarter. The quarterly net loss in June 2021 was Rs. 48.69 crores, which has seen a sharp decline by nearly 106.35% from a net profit of Rs. 766.39 crores in June 2020. In June 2021, the reported operating profit was at Rs. 199.96 crores, which is also reduced by 78.15% as compared to an operating profit of Rs. 915.08 crores for the quarter ending in June 2020. From Rs. 69.21 in June 2020, the EPS of Wockhardt Ltd has decreased to (Rs. 4.40) per share in June 2021. WOCKPHARMA’s stock closed at Rs. 488.50 on 17th August’2021 (NSE) and has returned -2.36% in the last six months and 49.78% in the previous year.

Registered Address

D-4 MIDC, Chikalthana, Aurangabad., Maharashtra, 431006

Tel : 91-240-6694444
Email : investorrelations:wockhardt.com
Website : http://www.wockhardt.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 532300
NSE Code : WOCKPHARMA
Book Closure Date (Month) :
BSE Group : A
ISIN : INE049B01025

FAQ’s on Wockhardt Ltd Shares

You can buy Wockhardt Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Wockhardt Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 14, 2024 03:58 PM the closing price of Wockhardt Ltd was Rs.570.85.

The latest PE ratio of Wockhardt Ltd as of Jun 14, 2024 03:58 PM is 0.00

The latest PB ratio of Wockhardt Ltd as of Jun 14, 2024 03:58 PM is 0.38

The 52-week high of Wockhardt Ltd share price is Rs. 630.00 while the 52-week low is Rs. 213.00

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 14, 2024 03:58 PM, the market cap of Wockhardt Ltd stood at Rs. 8,756.90.

Download App

Download Our App

Play Store App Store
market app